The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates

Aymen N Naguib

Status: Withdrawn

Conditions: Congenital Heart Disease

Treatments: Procedure: Acute Normovolemic Hemodilution; Drug: Tranexamic Acid

Study type: Observational

Funder types: Other

Identifiers

NCT01914211

IRB13-00350

Details and patient eligibility

About

This is an observational, prospective study to evaluate the role of tranexamic acid in reducing blood transfusion in neonates undergoing cardiopulmonary bypass.

Sex: All

Ages: Under 28 days old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All neonates undergoing arterial switch or aortic arch procedure utilizing cardiopulmonary bypass (CPB).

Exclusion criteria

• Jehovah's witness patients.

Trial design

0 participants in 2 patient groups

Acute Normovolemic Hemodilution

Description:

Patients that receive acute normovolemic hemodilution prior to surgery.

Treatment:

Procedure: Acute Normovolemic Hemodilution

Tranexamic Acid

Description:

Patients that receive tranexamic acid during surgery.

Treatment:

Drug: Tranexamic Acid